Capacity Development for Research into AIDS Associated malignancies (CADRE)

描述（由申请人提供）：尼日利亚艾滋病毒相关肿瘤研究能力发展（CADRE-尼日利亚）培训计划的目标是在尼日利亚人类病毒学研究所（IHV-尼日利亚）及其学术研究合作伙伴开展临床试验和癌症研究专业知识。该研究培训实现了四个目标：临床试验能力，癌症登记，癌症流行病学和一般研究能力建设。CADRE-Nigeria将在三年内举办13个短期培训班，41个中级培训班，3个学员深入的长期培训班。CADRE-Nigeria以Fogarty赞助的UM-IHV AITRP开创的“导师-导师”培训战略为基础（D43 TW 001041）通过聘请国际教师导师，一个尼日利亚教师导师和一个更初级的教师或非-教师实习生在培训三位一体，建立了一个关键质量的调查人员在尼日利亚研究合作伙伴网站，并创造了学术债券之间国际和尼日利亚教师促进持续的研究合作。该培训的主要成果是在尼日利亚阿布贾建立一个尼日利亚艾滋病毒-恶性肿瘤卓越中心--艾滋病临床试验联合会-尼日利亚（AMC-尼日利亚）中心，该中心实施NCI资助的AMC临床试验、艾滋病毒-恶性肿瘤研究，并作为国家培训中心，在尼日利亚的其他中心开展南南艾滋病毒相关恶性肿瘤能力建设。为了扩大艾滋病毒恶性肿瘤检测，肿瘤登记和癌症流行病学培训将利用IHV-尼日利亚PEPFAR计划中的140，000名艾滋病毒护理人员，为NCI癌症标本资源网络的AMC-尼日利亚试验和NIAID/NCI资助的西非国际流行病学数据库评估艾滋病（leDEA）网络的癌症研究议程提供丰富的病例转诊资源，两者都与IHV-尼日利亚有关。CADRE-尼日利亚的预期影响是参与越来越多的流行病学和临床试验方案，改善尼日利亚的癌症登记、艾滋病毒-癌症联系研究和艾滋病相关癌症的管理。相关性：CADRE-尼日利亚为尼日利亚的一个大型PEPFAR治疗方案中发现的艾滋病毒相关恶性肿瘤的临床试验和研究提供研究培训。

DESCRIPTION (provided by applicant): The Capacity Development for Research into HIV-Associated Malignancies in Nigeria (CADRE-Nigeria) training program targets development of clinical trials and cancer research expertise at the Institute of Human Virology, Nigeria (IHV-Nigeria) and its academic research partners. This research training implements four aims: clinical trials capacity, cancer registration, cancer epidemiology and general research capacity building. CADRE-Nigeria will conduct 13 short-term training courses, intermediate training for 41, and in depth long-range training for 3 trainees over 3 years. CADRE-Nigeria is anchored by the "mentor-the-mentor" training strategy pioneered by the Fogarty-sponsored UM-IHV AITRP (D43 TW001041) that builds sustainable capacity by engaging an international faculty mentor, a Nigerian faculty mentor and a more junior faculty or non-faculty trainee in a training triad that builds a critical mass of investigative staff at the Nigerian research partner site and creates an academic bond between the international and Nigerian faculty to promote sustained research collaboration. The major outcome of this training is a Nigerian HIV-malignancy center of excellence the AIDS Malignancy Clinical Trials Consortium-Nigeria (AMC-Nigeria) site in Abuja, Nigeria that implements NCI funded AMC clinical trials, HIV-malignancy research and serves as a national training center for south to south HIV-associated malignancy capacity development at other sites in Nigeria. To expand HIV-malignancy detection tumor registration and cancer epidemiology training will exploit the 140,000 in HIV care in IHV-Nigeria's PEPFAR program providing a rich resource for case referral for the AMC-Nigeria trials for NCI Cancer Specimen Resource networks and the cancer research agenda of the NIAID/NCI-funded West Africa International Epidemiologic Database to Evaluate AIDS (leDEA) network both linked to IHV-Nigeria. The expected impact of CADRE-Nigeria is participation in an increasing number of epidemiology and clinical trials protocols, improvement in cancer registration, HIV-Cancer linkage studies and management of AIDS Associated Cancers in Nigeria. RELEVANCE: CADRE-Nigeria provides research training for clinical trials and research of HIV-associated malignancy detected in a large PEPFAR treatment program in Nigeria.